Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
Rebecca A. Myers,(1) PharmD, Scott Wirth,(2) PharmD, BCOP, Sherry Williams,(3) PharmD, BCOP, and Patrick J. Kiel,(1,4) PharmD, BCPS, BCOP
1)Indiana University Simon Cancer Center–IU Health, Indianapolis, Indiana; 2)University of Illinois at Chicago Cancer Center and University of Illinois at Chicago College of Pharmacy, Chicago, Illinois; 3)Department of Pharmacy, The James Cancer Hospital and Solove Research Institute, Columbus, Ohio; 4)Indiana University School of Medicine, Indianapolis, Indiana
Authors’ disclosures of conflicts of interest are found at the end of this article.
Patrick J. Kiel, PharmD, BCPS, BCOP, 1030 W. Michigan Street, Suite 3307, Indianapolis, IN 46202. E-mail: email@example.com
J Adv Pract Oncol 2018;9(4):435–440 |
© 2018 Harborside™
Acute myeloid leukemia (AML) is a hematologic malignancy that affects predominantly older patients, with a median age of diagnosis around 67. Overall prognosis is poor; however, novel targeted therapies that can potentially improve outcomes in these patients have emerged in recent years. Mutations in isocitrate dehydrogenase (IDH) occur in 20% of AML diagnoses. IDH2 performs a crucial role in cellular metabolism, and when this enzyme is inhibited, the cell cannot rid itself of endogenous products and is thus marked for apoptosis. The US Food and Drug Administration (FDA) approved the first mutant IDH2 inhibitor, enasidenib, for patients with relapsed or refractory IDH2-mutated AML detected by an FDA-approved test.
For access to the full length article, please sign in